Viewing Study NCT03219333

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:47 AM
Ignite Modification Date: 2026-03-08 @ 11:26 PM
Study NCT ID: NCT03219333
Status: COMPLETED
Last Update Posted: 2024-08-27
First Post: 2017-07-13
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Sponsor: Astellas Pharma Inc
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Carcinoma, Transitional Cell View
None Urinary Bladder Neoplasms View
None Urologic Neoplasms View
None Renal Pelvis Neoplasms View
None Urothelial Cancer View
None Ureteral Neoplasms View
None Urethral Neoplasms View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Enfortumab vedotin View
None Metastatic Urothelial Cancer View
None ASG-22CE View
None Locally Advanced Urothelial Cancer View
None Antibody-Drug Conjugate View
None Nectin-4 View
None Platinum-naïve View
None Cisplatin-ineligible View
None Antineoplastic Agents View
None Drug Therapy View
None ASG-22ME View